表紙:生物製剤受託開発の市場規模、シェア、動向分析レポート:ソース別、サービスタイプ別、適応症別、地域別、セグメント予測:2023年~2030年
市場調査レポート
商品コード
1301078

生物製剤受託開発の市場規模、シェア、動向分析レポート:ソース別、サービスタイプ別、適応症別、地域別、セグメント予測:2023年~2030年

Biologics Contract Development Market Size, Share & Trends Analysis Report By Source (Mammalian, Microbial), By Service Type, By Indication (Oncology, Immunological Disorders), By Region And Segment Forecasts, 2023 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
生物製剤受託開発の市場規模、シェア、動向分析レポート:ソース別、サービスタイプ別、適応症別、地域別、セグメント予測:2023年~2030年
出版日: 2023年06月19日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

生物製剤受託開発市場の成長と動向

GrandView Research, Inc.の最新レポートによると、世界の生物製剤受託開発市場規模は2023年から2030年にかけてCAGR 8.1%で拡大し、2030年には138億米ドルに達すると予測されています。

市場促進要因には、細胞株、上流・下流工程、分析法、製剤の開発などのサービスを提供する組織が含まれます。これらの組織は、薬剤スクリーニング、遺伝子機能研究、生物製剤の製造など、いくつかの重要な用途で広く使用される安定した細胞株の開発・製造を専門としています。

バイオ製薬会社とCDOの間でM&Aや共同研究が活発化していることも、市場の成長を後押しする要因のひとつであり、財務的な安定と高度で専門的な技術の融合を可能にしています。例えば、2022年9月、Lonza.は、mRNAを開発するためのDNAの異なるソースで製品ポートフォリオを拡大するために、バイオテクノロジー企業Touchlightと提携しました。Touchlight社は、Lonza社の新規技術である犬骨DNA(dbDNA)へのアクセスを得るために提携しました。

多くのバイオ製薬企業や製薬会社は、アウトソーシングを行うことで、企業のワークフロー(スピード)を加速させ、独自の専門サービスを提供し、医薬品開発コストを削減し、専門知識を提供することができるため、ますますアウトソーシングを検討するようになっています。このような要因が生物製剤開発受託業界の成長を後押しすると予想されます。

COVID-19パンデミックの間、ほとんどの臨床試験はCOVID-19を治療するための新しい治療法を開発することに集中していました。しかし、パンデミック後の期間では、罹患率の上昇に起因するがんに調査が集中すると予想されます。モノクローナル抗体などの生物製剤は、がんの治療において大きな人気を博しています。がん治療における生物製剤の高い可能性とがん研究の増加は、今後数年間の市場の成長を支える可能性が高いです。

生物製剤受託開発市場レポートハイライト

  • 2022年には哺乳動物由来が52.0%以上のシェアで最大の製品セグメントに浮上。
  • 多くの企業が組換えタンパク質やモノクローナル抗体(MAB)の生産を外注することを選択しているため、プロセス開発は予測期間中に最も高いCAGRを記録すると予想されます。
  • 2019年の世界市場は北米が支配。戦略的買収とパートナーシップの増加、専門的な検査サービスに対する需要の増加が好影響を与えるとみられる
  • アジア太平洋地域は予測期間中に最も高いCAGRを記録すると予想されます。これは、世界の要件に合わせて臨床試験の評価基準を変更するために規制機関が行った様々な改正と、アジア太平洋地域における投資の増加別ものです。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
  • 調査手法
  • 情報調達
  • 情報またはデータ分析
  • 市場の形成と検証
  • 地域ごとの市場計算
  • モデル詳細
  • 一次情報のリスト
  • 略語のリスト
  • 二次情報のリスト
  • 目的

第2章 エグゼクティブサマリー

  • 市場の見通し

第3章 生物製剤受託開発市場:変数、動向、範囲

  • 市場セグメンテーションと範囲
  • 市場力学
    • 市場促進要因分析
    • 先進テクノロジーの採用の増加
    • 増加する合併と協力
    • 新興諸国での臨床試験に有利な環境
    • 研究開発活動の外部委託の増加
    • 市場抑制要因分析
    • 知的財産権の問題
  • 普及と成長の見通しマッピング
  • 生物製剤受託開発:市場分析ツール
    • 業界分析- ポーターのファイブフォース
    • PESTEL分析
  • COVID-19による生物製剤受託開発市場への影響

第4章 生物製剤受託開発市場:ソースタイプのセグメント分析

  • 生物製剤受託開発市場:市場シェア分析、2022年および2030年
    • 微生物
    • 哺乳動物
    • その他

第5章 生物製剤受託開発市場:サービスのセグメント分析

  • 生物製剤受託開発市場:市場シェア分析、2022年および2030年
  • 細胞株開発
    • 細胞株開発市場、2018年~2030年
    • プロセス開発
    • 下流工程の開発
    • 下流工程、製品別
  • その他のサービス(品質および規制サービスなど)
    • その他市場、2018-2030

第6章 生物製剤受託開発市場:適応症のセグメント分析

  • 生物製剤受託開発市場:市場シェア分析、2022年および2030年
  • 腫瘍学
  • 免疫疾患
  • 心血管疾患
  • 血液疾患
  • その他

第7章 生物製剤受託開発市場:地域の分析

  • 生物製剤の契約開発:地域市場シェア分析、2022年および2030年
  • 北米
    • 北米の生物製剤受託開発市場、2018年~2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州の生物製剤受託開発市場、2018年~2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋地域
    • アジア太平洋地域の生物製剤受託開発市場、2018年~2030年
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
  • ラテンアメリカ
    • ラテンアメリカの生物製剤受託開発市場、2018年~2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
  • MEA
    • MEAの生物製剤受託開発市場、2018年~2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第8章 企業プロファイル

  • 競合情勢
  • 企業プロファイル
    • Wuxi Biologics
    • Abzena Ltd
    • Fujifilm Diosynth Biotechnologies
    • Kbi Biopharma
    • Agc Biologics
    • Thermo Fischer Scientific Inc.
    • Curia Global, Inc
    • Genscript
    • Bionova Scientific Inc.
    • Bioxcellence(Boehringer Ingelheim Biopharmaceuticals Gmbh)
    • Stc Biologics
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Biologics Contract Development Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 5 Global Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 6 Global Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 7 North America Biologics Contract Development Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 9 North America Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 10 North America Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 12 U.S. Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 13 U.S. Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 14 Canada Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 15 Canada Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 16 Canada Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 17 Europe Biologics Contract Development Market, By Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 19 Europe Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 20 Europe Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 21 Germany Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 22 Germany Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 23 Germany Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 24 UK Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 25 UK Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 26 UK Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 27 France Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 28 France Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 29 France Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 30 Italy Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 31 Italy Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 32 Italy Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 33 Spain Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 34 Spain Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 35 Spain Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 36 Denmark Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 37 Denmark Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 38 Denmark Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 39 Sweden Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 40 Sweden Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 41 Sweden Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 42 Norway Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 43 Norway Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 44 Norway Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Biologics Contract Development Market, By Country, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 49 China Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 50 China Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 51 China Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 52 Japan Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 53 Japan Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 54 Japan Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 55 India Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 56 India Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 57 India Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 58 Australia Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 59 Australia Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 60 Australia Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 61 South Korea Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 62 South Korea Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 63 South Korea Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 64 Thailand Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 65 Thailand Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 66 Thailand Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 67 Latin America Biologics Contract Development Market, By Country, 2018 - 2030 (USD Million)
  • Table 68 Latin America Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 69 Latin America Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 70 Latin America Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 71 Brazil Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 72 Brazil Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 73 Brazil Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 74 Mexico Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 75 Mexico Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 76 Mexico Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 77 Argentina Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 78 Argentina Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 79 Argentina Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 80 Colombia Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 81 Colombia Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 82 Colombia Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 83 Middle East and Africa Biologics Contract Development Market, By Country, 2018 - 2030 (USD Million)
  • Table 84 Middle East and Africa Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 85 Middle East and Africa Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 86 Middle East and Africa Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 87 South Africa Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 88 South Africa Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 89 South Africa Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 92 Saudi Arabia Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 93 UAE Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 94 UAE Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 95 UAE Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Biologics Contract Development Market, by Source, 2018 - 2030 (USD Million)
  • Table 97 Kuwait Biologics Contract Development Market, by Service, 2018 - 2030 (USD Million)
  • Table 98 Kuwait Biologics Contract Development Market, by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 Biologics Contract Development market snapshot (2022)
  • Fig. 11 Biologics Contract Development market segmentation
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 Biologics Contract Development market product type outlook: Segment dashboard
  • Fig. 18 Biologics Contract Development market: product movement analysis
  • Fig. 19 Microbial market, 2018 - 2030 (USD Million)
  • Fig. 20 Mammalian market, 2018 - 2030 (USD Million)
  • Fig. 21 Others market, 2018 - 2030 (USD Million)
  • Fig. 22 Biologics Contract Development market service outlook: Segment dashboard
  • Fig. 23 Biologics Contract Development market: product movement analysis
  • Fig. 24 Cell Line Development market, 2018 - 2030 (USD Million)
  • Fig. 25 Microbial Cell Line Development market, 2018 - 2030 (USD Million)
  • Fig. 26 Mammalian Cell Line Development market, 2018 - 2030 (USD Million)
  • Fig. 27 Others market, 2018 - 2030 (USD Million)
  • Fig. 28 Process development market, 2018 - 2030 (USD Million)
  • Fig. 29 Upstream Process Development market, 2018 - 2030 (USD Million)
  • Fig. 30 Microbial market, 2018 - 2030 (USD Million)
  • Fig. 31 Mammalian market, 2018 - 2030 (USD Million)
  • Fig. 32 Others market, 2018 - 2030 (USD Million)
  • Fig. 33 Downstream Process Development market, 2018 - 2030 (USD Million)
  • Fig. 34 Impurity, isolation, & identification market, 2018 - 2030 (USD Million)
  • Fig. 35 Physicochemical characterization market, 2018 - 2030 (USD Million)
  • Fig. 36 Pharmaceutical analysis market, 2018 - 2030 (USD Million)
  • Fig. 37 Others market, 2018 - 2030 (USD Million)
  • Fig. 38 MABS (Monoclonal Antibodies) market, 2018 - 2030 (USD Million)
  • Fig. 39 Recombinant proteins market, 2018 - 2030 (USD Million)
  • Fig. 40 Others market, 2018 - 2030 (USD Million)
  • Fig. 41 Others market, 2018 - 2030 (USD Million)
  • Fig. 42 Biologics Contract Development market indication outlook: Segment dashboard
  • Fig. 43 Biologics Contract Development market: indication movement analysis
  • Fig. 44 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 45 Immunological disorders market, 2018 - 2030 (USD Million)
  • Fig. 46 Cardiovascular disorders market, 2018 - 2030 (USD Million)
  • Fig. 47 Hematological disorders market, 2018 - 2030 (USD Million)
  • Fig. 48 Others market, 2018 - 2030 (USD Million)
  • Fig. 49 Regional market: Key takeaways
  • Fig. 50 Regional outlook, 2022 & 2030
  • Fig. 51 North America market, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 53 Canada market, 2018 - 2030 (USD Million)
  • Fig. 54 Europe market, 2018 - 2030 (USD Million)
  • Fig. 55 UK market, 2018 - 2030 (USD Million)
  • Fig. 56 Germany market, 2018 - 2030 (USD Million)
  • Fig. 57 France market, 2018 - 2030 (USD Million)
  • Fig. 58 Italy market, 2018 - 2030 (USD Million)
  • Fig. 59 Spain market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 61 China market, 2018 - 2030 (USD Million)
  • Fig. 62 India market, 2018 - 2030 (USD Million)
  • Fig. 63 Japan market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia market, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 68 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 70 Colombia market, 2018 - 2030 (USD Million)
  • Fig. 71 MEA market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68038-983-8

Biologics Contract Development Market Growth & Trends

The global biologics contract development market size is expected to reach USD 13.8 billion by 2030, expanding at 8.1% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. Key drivers attributed to the growth include rising adoption of advanced technologies by biologics manufacturers, M&A, and clinical trials in developing nations.The market includes organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in several important applications, including drug screening, gene functional studies, and biologic production.

Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth allowing more financial stability and amalgamation of advanced & specialized technologies. For instance, in September 2022, Lonza., collaborated with biotechnology company Touchlight to expand its product portfolio with different sources of DNA for developing mRNA. Touchlight partnered to gain access to Lonza's novel doggybone DNA (dbDNA) technology.

Many biopharma and Pharma companies are increasingly looking to outsource their activities as it helps accelerate the workflow (speed) of the company, provide unique specialized services, decrease drug development costs, and provide expertise. These factors are expected to boost the biologics contract development industry's growth.

During the COVID-19 pandemic, most clinical trials were focused on developing new therapies for treating COVID-19. However, in the post-pandemic period, research is expected to focus on cancer owing to rising incidences. Biologics such as monoclonal antibodies have gained significant popularity in treating cancer. The high potential of biologics in treating cancer and the growing number of cancer studies are likely to support the growth of the market in the coming years.

Biologics Contract Development Market Report Highlights

  • Mammalian source emerged as the largest product segment in 2022 with over 52.0% share, as the majority of research is being carried out using mammalian cell lines
  • Process development is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource the production of recombinant proteins and monoclonal antibodies (MABs)
  • North America dominated the global market in 2019. An increase in strategic acquisitions & partnerships and a rise in demand for specialized testing services are likely to have a positive impact
  • Asia Pacific is expected to register the highest CAGR over the forecast period, owing to various amendments made by regulatory organizations to change clinical trials evaluation standards in tandem with global requirements and rising investment in the Asia Pacific region

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Source Type
    • 1.1.2 Service Type
    • 1.1.3 Disease Indication Type
    • 1.1.4 Regional Scope
    • 1.1.5 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Region-Wise Market Calculation
    • 1.6.1 Region-Wise Market: Base Estimates
    • 1.6.2 Global Market: Cagr Calculation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis (Model 1)
    • 1.7.2 Volume Price Analysis (Model 2)
      • 1.7.2.1 Service Segment Analysis
  • 1.8 List Of Primary Sources
  • 1.9 List Of Abbreviations
  • 1.10 List Of Secondary Sources
  • 1.11 Objectives
    • 1.11.1 Objective - 1:
    • 1.11.2 Objective - 2:
    • 1.11.3 Objective - 3:
    • 1.11.4 Objective - 4:

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Biologics Contract Development Market: Variables, Trends, & Scope

  • 3.1 Market Segmentation And Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
    • 3.2.2 Increasing Adoption Of Advanced Technologies
    • 3.2.3 Increasing Mergers And Collaborations
    • 3.2.4 Favorable Environment For Clinical Trials In Developing Countries
    • 3.2.5 Increasing Outsourcing Of R&D Activities
    • 3.2.6 Market Restraint Analysis
    • 3.2.7 Intellectual Property Rights Issues
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 Biologics Contract Development: Market Analysis Tools
    • 3.4.1 Industry Analysis - Porter's Five Forces
    • 3.4.2 Pestel Analysis
  • 3.5 COVID-19 Impact On The Biologics Contract Development Market

Chapter 4 Biologics Contract Development Market: Source Type Segment Analysis

  • 4.1 Biologics Contract Development Market: Market Share Analysis, 2022 & 2030
    • 4.1.1 Microbial
      • 4.1.1.1 Microbial Market, 2018 - 2030 (USD Million)
      • 4.1.1.2 Mammalian
      • 4.1.1.2.1 Mammalian Market, 2018 - 2030 (USD Million)
      • 4.1.1.3 Others
      • 4.1.1.3.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Biologics Contract Development Market: Service Segment Analysis

  • 5.1 Biologics Contract Development Market: Market Share Analysis, 2022 & 2030
  • 5.2 Cell Line Development
    • 5.2.1 Cell Line Development Market, 2018 - 2030 (USD Million)
      • 5.2.1.1 Microbial Cell Line Development
      • 5.2.1.1.1 Microbial Cell Line Development Market, 2018 - 2030 (USD Million)
      • 5.2.1.2 Mammalian Cell Line Development
      • 5.2.1.2.1 Mammalian Cell Line Development Market, 2018 - 2030 (USD Million)
      • 5.2.1.3 Others
      • 5.2.1.3.1 Others Market, 2018 - 2030 (USD Million)
    • 5.2.2 Process Development
      • 5.2.2.1 Process Development market, 2018 - 2030 (USD Million)
      • 5.2.2.2 Upstream Process Development
      • 5.2.2.1.1 Upstream Process Development Market, 2018 - 2030 (USD Million)
      • 5.2.2.1.1.1 Microbial
      • 5.2.2.1.1.1.1 Microbial Market, 2018 - 2030 (USD Million)
      • 5.2.2.1.2.1 Mammalian
      • 5.2.2.1.2.1.1 Mammalian Market, 2018 - 2030 (USD Million)
      • 5.2.2.1.3.1 Others
      • 5.2.2.1.3.1.1 Others Market, 2018 - 2030 (USD Million)
    • 5.2.3 Downstream Process Development
      • 5.2.3.1 Downstream Process Development, 2018 - 2030 (USD Million)
      • 5.2.3.1.1 Impurity, Isolation, & Identification
      • 5.2.3.1.1.1 Impurity, Isolation, & Identification Market, 2018 - 2030 (USD Million)
      • 5.2.3.1.2 Physicochemical Characterization
      • 5.2.3.1.2.1 Physicochemical Characterization Market, 2018 - 2030 (USD Million)
      • 5.2.3.1.3 Pharmaceutical Analysis
      • 5.2.3.1.3.1 Pharmaceutical Analysis Market, 2018 - 2030 (USD Million)
      • 5.2.3.1.4 Others
      • 5.2.3.1.4.1 Others Market, 2018 - 2030 (USD Million)
    • 5.3.4 Downstream Process, By Product
      • 5.3.4.1 Mabs (Monoclonal Antibodies)
      • 5.3.4.1.1 Mabs (Monoclonal Antibodies) Market, 2018 - 2030 (USD Million)
      • 5.3.4.2. Recombinant Proteins
      • 5.3.4.2.1 Recombinant Proteins Analysis Market, 2018 - 2030 (USD Million)
      • 5.3.4.3 Others
      • 5.3.4.3.1 Others Market, 2018 - 2030 (USD Million)
  • 5.3 Other Services (Quality And Regulatory Services, Etc)
    • 5.3.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Biologics Contract Development Market: Indication Segment Analysis

  • 6.1 Biologics Contract Development Market: Market Share Analysis, 2022 & 2030
  • 6.2 Oncology
    • 6.2.1 Oncology Market, 2018 - 2030 (USD Million)
  • 6.3 Immunological Disorders
    • 6.3.1 Immunological Disorders Market, 2018 - 2030 (USD Million)
  • 6.4 Cardiovascular Disorders
    • 6.4.1 Cardiovascular Disorders Market, 2018 - 2030 (USD Million)
  • 6.5 Hematological Disorders
    • 6.5.1 Hematological Disorders Market, 2018 - 2030 (USD Million)
  • 6.6 Others
    • 6.6.1 others Market, 2018 - 2030 (USD Million)

Chapter 7 Biologics Contract Development Market: Regional Analysis

  • 7.1 Biologics Contract Development: Regional Market Share Analysis, 2022 & 2030
  • 7.2 North America
    • 7.2.1 North America Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.2.3 Canada
      • 7.2.3.1 Canada Biologics Contract Development Market, 2018 - 2030 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.3.2 UK
      • 7.3.2.1 UK Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.3.3 Germany
      • 7.3.3.1 Germany Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.3.4 France
      • 7.3.4.1 France Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.3.5 Italy
      • 7.3.5.1 Italy Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.3.6 Spain
      • 7.3.6.1 Spain Biologics Contract Development Market, 2018 - 2030 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.4.2 China
      • 7.4.2.1 China Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.4.3 India
      • 7.4.3.1 India Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.4.4 Japan
      • 7.4.4.1 Japan Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.4.5 Australia
      • 7.4.5.1 Australia Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.4.6 South Korea
      • 7.4.6.1 South Korea Biologics Contract Development Market, 2018 - 2030 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.5.5 Colombia
      • 7.5.5.1 Colombia Biologics Contract Development Market, 2018 - 2030 (USD Million)
  • 7.6 MEA
    • 7.6.1 MEA Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Biologics Contract Development Market, 2018 - 2030 (USD Million)
    • 7.6.4 UAE
      • 7.6.4.1 UAE Biologics Contract Development Market, 2018 - 2030 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Competitive Landscape
  • 8.2 Company Profile
    • 8.2.1 Wuxi Biologics
      • 8.2.1.1 Company Overview
      • 8.2.1.2 Financial Performance
      • 8.2.1.3 Service Benchmarking
      • 8.2.1.4 Strategic Initiatives
    • 8.2.2 Abzena Ltd
      • 8.2.2.1 Company Overview
      • 8.2.2.2 Service Benchmarking
      • 8.2.2.3 Strategic Initiatives:
    • 8.2.3 Fujifilm Diosynth Biotechnologies
      • 8.2.3.1 Company Overview
      • 8.2.3.2 Financial Performance
      • 8.2.3.3 Service Benchmarking
      • 8.2.3.4 Strategic Initiatives
    • 8.2.4 Kbi Biopharma
      • 8.2.4.1 Company Overview
      • 8.2.4.2 Service Benchmarking
      • 8.2.4.3 Strategic Initiatives
    • 8.2.5 Agc Biologics
      • 8.2.5.1 Company Overview
      • 8.2.5.2 Financial Performance
      • 8.2.5.3 Service Benchmarking
      • 8.2.5.4 Strategic Initiatives:
    • 8.2.6 Thermo Fischer Scientific Inc.
      • 8.2.6.1 Company Overview
      • 8.2.6.2 Financial Performance
      • 8.2.6.3 Service Benchmarking
      • 8.2.6.4 Strategic Initiatives:
    • 8.2.7 Curia Global, Inc
      • 8.2.7.1 Company Overview
      • 8.2.7.2 Service Benchmarking
      • 8.2.7.3 Strategic Initiatives:
    • 8.2.8 Genscript
      • 8.2.8.1 Company Overview
      • 8.2.8.2 Financial Performance
      • 8.2.8.3 Service Benchmarking
      • 8.2.8.4 Strategic Initiatives
    • 8.2.9 Bionova Scientific Inc.
      • 8.2.9.1 Company Overview
      • 8.2.9.2 Service Benchmarking
    • 8.2.10 Bioxcellence (Boehringer Ingelheim Biopharmaceuticals Gmbh)
      • 8.2.10.1 Company Overview
      • 8.2.10.2 Financial Performance
      • 8.2.10.3 Service Benchmarking
      • 8.2.10.4 Strategic Initiatives:
    • 8.2.11 Stc Biologics
      • 8.2.11.1 Company Overview
      • 8.2.11.2 Service Benchmarking